Because of the well documented anti-tumor activity of PX-12 and auranofin, we used these drugs, along with knockdown of Trx1 and TrxR1, as tools to study the cytoprotective role of Trx1 and TrxR1 in MM. This evidence concerns the gene TXN and Miyoshi myopathy.